A thermometer inside the refrigerator is not excessive
Records are scattered, titration steps are missed, and avoidable prior authorization denials delay therapy
Conclusion Four completed trials now confirm retatrutide's efficacy across different populations, doses, and durations: Phase 2 (338 patients, 48 weeks): 24.2% proof of concept TRIUMPH-4 (445 patients, 68 weeks): 28.7% first Phase 3 confirmation TRIUMPH-1 (2,339 patients, 80 weeks): 28.3% pivotal confirmation in general obesity population TRIUMPH-1 extension (subset, 104 weeks): 30.3% weight loss continues beyond 80 weeks TRANSCEND-T2D-1 (537 patients, 40 weeks): 16.8% weight loss and -2.0% HbA1c in type 2 diabetes The consistency between TRIUMPH-4 (28.7%) and TRIUMPH-1 (28.3%) across two very different populations is the most important finding for obesity it means the results aren't driven by population-specific factors, they reflect the drug's fundamental mechanism
Submit a written appeal to your TRICARE regional contractor within 90 days of the denial
Mechanism of Action Semaglutide: Targets only the GLP-1 receptor, which helps regulate blood sugar and suppress appetite
